Allosteric Regulation

Allosteric regulation is the control of an enzyme's activity by a molecule that binds at a site other than the active site. Binding of this effector changes the enzyme's shape and therefore its catalytic activity, allowing pathways to respond rapidly to signals such as the accumulation of an end product. Allostery is one of the fastest and most widespread ways cells tune metabolism.

Definition

Allosteric regulation is the modulation of an enzyme's catalytic activity by the binding of an effector molecule at a site distinct from the active site, which alters the enzyme's conformation and thereby its affinity for substrate or its rate of catalysis.

Scope

This entry covers the definition of allosteric sites and effectors, cooperative binding in multi-subunit enzymes, the two classic quantitative models (concerted and sequential), and feedback inhibition as the canonical biological role. It treats allostery as a topic in enzymology and does not give clinical or pharmacological guidance.

Core questions

• How can binding at one site change activity at a distant active site?
• Why do many regulated enzymes show sigmoidal rather than hyperbolic kinetics?
• How do the concerted and sequential models explain cooperativity differently?
• How does feedback inhibition use allostery to keep pathways balanced?

Key concepts

• Allosteric site versus active site
• Allosteric effectors (activators and inhibitors)
• Cooperativity and sigmoidal kinetics
• Tense (T) and relaxed (R) states
• Homotropic and heterotropic effects
• Feedback (end-product) inhibition

Key theories

Concerted (MWC) model

Monod, Wyman and Changeux proposed that a symmetric oligomer switches all subunits together between a tense (low-affinity) and relaxed (high-affinity) state, with effectors shifting the pre-existing equilibrium between the two states.

Sequential (KNF) model

Koshland, Nemethy and Filmer proposed that ligand binding induces a conformational change in one subunit that progressively alters neighboring subunits, allowing intermediate states and a graded form of cooperativity.

Mechanisms

An allosteric enzyme has one or more regulatory sites separate from its catalytic site. When an effector binds a regulatory site, it stabilizes a particular conformation of the protein, shifting the balance between higher- and lower-activity states and thereby changing how readily substrate binds or is turned over. In multi-subunit enzymes this coupling produces cooperativity, so that the binding of substrate to one subunit influences the others and the rate-versus-substrate curve becomes sigmoidal. Two limiting descriptions are used: the concerted model, in which all subunits change state together around a single equilibrium, and the sequential model, in which binding induces stepwise changes that permit mixed states. Biologically, allostery underlies feedback inhibition, where the end product of a pathway binds an early enzyme and slows its own production, and it lets sensors such as the AMP-activated protein kinase respond to the cell's energy state.

Clinical relevance

Allosteric mechanisms underlie much of metabolic regulation and are exploited by allosteric drugs, so the concept is foundational for understanding biochemistry in medicine. This entry explains the molecular logic of allostery for reference and is not a basis for diagnosis or treatment decisions.

History

Allostery was conceptualized in the early 1960s to explain why certain regulated enzymes did not obey simple Michaelis-Menten kinetics and could be inhibited by molecules structurally unrelated to their substrates. The 1965 concerted model of Monod, Wyman and Changeux gave the idea a quantitative form, and Koshland, Nemethy and Filmer's 1966 sequential model offered an alternative account of cooperativity. The two models have since framed decades of study of regulated enzymes and remain reference points in enzymology.

Debates

Concerted versus sequential models of cooperativity

The MWC and KNF models make different assumptions about how subunits change conformation; real enzymes often show behavior intermediate between the two, and which framework best describes a given enzyme remains a classic point of analysis.

Key figures

• Jacques Monod
• Jeffries Wyman
• Jean-Pierre Changeux
• Daniel Koshland

Seminal works

• monod-1965
• koshland-1966

Frequently asked questions

What is the difference between an allosteric site and the active site?

The active site is where catalysis occurs; an allosteric site is a separate location where a regulatory molecule binds to change the enzyme's shape and thus its activity.

Why do allosteric enzymes often give a sigmoidal (S-shaped) activity curve?

Because binding at one subunit cooperatively affects the others, the enzyme switches more steeply from low to high activity over a narrow range of substrate or effector concentration.